Brintellix Tablets (Vortioxetine) Approved by the FDA for the Treatment of Major Depressive Disorder
Major depressive disorder (MDD) is a common, chronic medical illness that affects 5% to 8% of adults in the United States annually, which amounts to approximately 25 million people.
Gazyva (Obinutuzumab) for Chronic Lymphocytic Leukemia: First FDA-Approved Breakthrough Therapy in Oncology
Chronic lymphocytic leukemia (CLL), a monoclonal disorder characterized by progressive accumulation and proliferation of functionally incompetent B-cells, is the most frequently diagnosed leukemia in the United States.
Fetzima Extended-Release (Levomilnacipran) Receives FDA Approval for the Treatment of Major Depressive Disorder in Adults
Major depressive disorder (MDD), also known as clinical depression, is a chronic medical illness characterized by persistent sadness, loss of interest in normal activities, and in some cases, by physical symptoms.
Gilotrif (Afatinib): Second-Generation Tyrosine Kinase Inhibitor Indicated for the First-Line Treatment of Patients with Non–Small-Cell Lung Cancer and EGFR Mutation
Lung cancer is one of the most frequently diagnosed cancers, as well as the leading cause of cancer-related mortality in the United States.
Ilaris (Canakinumab) Receives a New Indication for the Treatment of Systemic Juvenile Idiopathic Arthritis
Systemic juvenile idiopathic arthritis (SJIA) is a rare inflammatory disease, affecting approximately 10% of children diagnosed with juvenile idiopathic arthritis in the United States.
Imbruvica (Ibrutinib) for Mantle-Cell Lymphoma: First Bruton’s Tyrosine Kinase Inhibitor Approved for Use in a Hematologic Malignancy
Mantle-cell lymphoma (MCL) is a rare malignancy, comprising approximately 5% of all cases of non-Hodgkin lymphoma.
Injectafer (Ferric Carboxymaltose Injection) Receives FDA Approval for the Treatment of Iron-Deficiency Anemia
Iron-deficiency anemia is the most common form of anemia. Iron plays a key role in producing hemoglobin (Hb) in red blood cells, which enables red blood cells to carry oxygen effectively to the body’s tissues.
Invokana (Canagliflozin): First-in-Class SGLT2 Inhibitor Approved for the Treatment of Type 2 Diabetes
Diabetes affects an estimated 25.8 million people in the United States—a staggering 8.3% of the population.
Kadcyla (Ado-Trastuzumab Emtansine): First Antibody-Drug Conjugate Approved for the Treatment of HER2-Positive Metastatic Breast Cancer
Approximately 25% of women who are diagnosed with breast cancer have HER2-positive tumors. The HER2 gene, which resides on chromosome 17, directs tumor cells to manufacture HER2 protein.
Mirvaso (Brimonidine): First Topical Gel Approved by the FDA for the Treatment of Facial Erythema of Rosacea
Rosacea, a chronic and potentially life-disrupting skin condition, affects an estimated 16 million people in the United States.
Page 2 of 4
Results 11 - 20 of 33
Results 11 - 20 of 33